Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.63 |
| ▸ | HTT | P42858 | 4/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.57 |
| ▸ | PDE1A | P54750 | 1/20 | 0.56 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.56 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4470996 | 0.88 | ALDH1A1 (0.79) | RXFP1ALDH1A1HTTHSD17B10USP2 | |
| SCHEMBL4460765 | 0.82 | PDE1A (0.77) | RXFP1ALDH1A1HTTHSD17B10USP2 | |
| SCHEMBL683586 | 0.81 | ALDH1A1 (0.74) | RXFP1ALDH1A1HTTHSD17B10USP2 | |
| SCHEMBL4468785 | 0.78 | HTR7 (0.64) | ALDH1A1HTTHSD17B10USP2PDE1A | |
| SCHEMBL10775620 | 0.77 | ALDH1A1 (0.73) | RXFP1ALDH1A1HTTHSD17B10USP2 | |
| SCHEMBL4471523 | 0.77 | PDE1A (0.57) | ALDH1A1HSD17B10USP2PDE1APDE1B | |
| SCHEMBL4462967 | 0.76 | PDE1A (0.61) | ALDH1A1HSD17B10USP2PDE1APDE1B | |
| SCHEMBL4480786 | 0.76 | PDE1A (0.58) | ALDH1A1HTTHSD17B10USP2PDE1A | |
| SCHEMBL10775616 | 0.76 | ALDH1A1 (0.65) | RXFP1ALDH1A1HTTHSD17B10USP2 | |
| SCHEMBL4462921 | 0.75 | PDE1A (0.60) | ALDH1A1PDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550468-B2 | Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase | CHEN ING-JUN | 2009-06-23 | — | — | US | disclosed |
| US-20050209242-A1 | Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase | CHEN ING-JUN | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209242-A1 | Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase | PDE3A, PDE5A, PDE3B | RXFP1 301/4885ALDH1A1 1215/4885HTT 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.